Status:

COMPLETED

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Lead Sponsor:

Bayer

Conditions:

Multiple Sclerosis, Relapsing-Remitting

Eligibility:

All Genders

18-55 years

Phase:

PHASE3

Brief Summary

The BEYOND Follow-Up study will give patients who participated in the preceding BEYOND study the opportunity to continue treatment with the 500µg dose of interferon beta (IFNB) 1b and will further inv...

Detailed Description

Phase A (3 arm parallel group): All patients randomized during the BEYOND study (Bayer 306440) to either IFNB 1b group (250µg or 500µg) will continue their previously assigned study medication, applyi...

Eligibility Criteria

Inclusion

  • Completion of the BEYOND study 306440 as scheduled
  • Relapsing multiple sclerosis
  • Medical assessment by the investigator that there is no objection to the patient's participation in this trial considering the medical experience from study 306440. Special attention should be given to laboratory abnormalities and clinically relevant liver, renal and bone-marrow dysfunction.
  • Females of child-bearing potential:
  • Agreement to practice adequate contraception methods and
  • Negative pregnancy test and
  • No lactation
  • Written informed consent

Exclusion

  • Serious or acute heart diseases
  • History of severe depression or suicide attempt
  • Epilepsy not adequately controlled by treatment
  • Known allergy to IFNs, to human albumin or to mannitol
  • Medical, psychiatric or other conditions that compromise the patient's ability to understand the patient information, to give informed consent, to comply with the trial protocol, or to complete the study

Key Trial Info

Start Date :

May 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2008

Estimated Enrollment :

1420 Patients enrolled

Trial Details

Trial ID

NCT00459667

Start Date

May 1 2007

End Date

March 1 2008

Last Update

April 23 2015

Active Locations (184)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 46 (184 locations)

1

Birmingham, Alabama, United States, 35294-7340

2

Cullman, Alabama, United States, 35058

3

Phoenix, Arizona, United States, 85013

4

Tucson, Arizona, United States, 85741